PRAG-MS
What was tested
Treatment tested
- Fingolimod
- DIMETIL-FUMARATO
What it measured
Main measures
The time for losing the NEDA status
Other measures (1)
Annual relapse rate; Number of Gd+ MRI Lesion; Brain volume loss; Percentage of patients with confirmed increase of 1 point on PDDSS; Percentage of patients with a confirmed increase of 1 point on the EDSS scale; Change in gait performance assessed by inertial sensors; Percentage of patients maintaining patients-NEDA status; 8. Change in cognitive impairment index (CII) assessed by Brief Repeatabl
Disability progressionRelapsesMRI lesionsBrain volume lossThinking and memoryFatigueWalking and mobilityMood and sleepQuality of life (reported by participants)
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Sept 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error